TrovaGene (TROV) Lifted to “Sell” at ValuEngine

ValuEngine upgraded shares of TrovaGene (NASDAQ:TROV) from a strong sell rating to a sell rating in a report released on Friday, February 2nd.

Several other research analysts also recently weighed in on the stock. Maxim Group reissued a hold rating on shares of TrovaGene in a research note on Wednesday, January 24th. HC Wainwright began coverage on shares of TrovaGene in a research note on Thursday, December 21st. They issued a buy rating and a $1.00 target price for the company. Finally, downgraded shares of TrovaGene from a buy rating to a hold rating in a research note on Wednesday, November 15th. Two analysts have rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the stock. The company presently has a consensus rating of Hold and an average price target of $3.70.

TrovaGene (NASDAQ TROV) opened at $0.33 on Friday. TrovaGene has a one year low of $0.23 and a one year high of $2.14. The firm has a market cap of $17.46, a PE ratio of -0.34 and a beta of 0.26.

A hedge fund recently raised its stake in TrovaGene stock. Goldman Sachs Group Inc. lifted its position in shares of TrovaGene Inc (NASDAQ:TROV) by 1,079.5% in the second quarter, according to its most recent 13F filing with the SEC. The firm owned 278,186 shares of the medical research company’s stock after purchasing an additional 254,601 shares during the quarter. Goldman Sachs Group Inc. owned about 0.75% of TrovaGene worth $351,000 as of its most recent filing with the SEC. Institutional investors own 9.51% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This news story was originally posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international trademark & copyright laws. The correct version of this news story can be accessed at

About TrovaGene

Trovagene, Inc is a clinical-stage, precision medicine oncology therapeutics company. The Company’s lead drug candidate, PCM-075, is a Polo-like Kinase 1 (PLK1) selective adenosine triphosphate (ATP) competitive inhibitor. PCM-075 has shown preclinical antitumor activity as a single agent and in synergy combinations with more than ten different chemotherapeutics and targeted therapies, such as Zytiga (abiraterone acetate), Beleodaq (belinostat), Quizartinib (AC220), a development stage FLT3 inhibitor, and Velcade (bortezomib) in Acute Myeloid Leukemia (AML), metastatic Castration-Resistant Prostate Cancer (mCRPC) and other liquid and solid tumor cancers.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for TrovaGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TrovaGene and related companies with's FREE daily email newsletter.

Leave a Reply